Research & Development

UNION therapeutics to acquire licence for Covid-19 technologies developed by TFF Pharmaceuticals

UNION therapeutics announced the completion of an agreement with TFF Pharmaceuticals (TFF) to acquire an option to obtain a worldwide exclusive license for the use of their Thin Film Freezing technology in combination with niclosamide to focus on treatments for COVID-19.

GeneCentric, Janssen collaborate to study genomic drug response biomarkers for NMIBC

GeneCentric Therapeutics has announced a research collaboration with Janssen Research & Development on RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC).

Bayer to buy UK biotech company KaNDy Therapeutics

Bayer has agreed to acquire UK-based clinical-stage biotech company KaNDy Therapeutics for an upfront consideration of $425m.

Ligand Pharmaceuticals to buy Pfenex for up to $516m

Ligand Pharmaceuticals has agreed to acquire development and licencing biotechnology company Pfenex in a deal valued at around $516m.

Seismic Bio partners with Twist Bioscience for discovery and optimisation of antibodies

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Seismic Bio, an immuno-oncology company focused on bispecific antibody development, today announced a partnership for the discovery and optimization of antibodies to high-value immuno-oncology targets.

Pfizer says Covid-19 vaccine may be needed regularly

Pfizer is considering a long-term commercial strategy for its Covid-19 vaccine, anticipating that the novel coronavirus could endure and a one-time vaccine dose may not be enough.

Nura Bio launches to discover and develop neuroprotective drug

Nura Bio, a biopharma company created to discover and develop life-changing neuroprotective drugs, announced its official launch.

Karuna Therapeutics and PsychoGenics announce drug discovery collaboration

Karuna Therapeutics announced that the companies have entered a multi-year drug discovery and development agreement to identify potential novel drug candidates for the treatment of severe neuropsychiatric disorders.

Daiichi Sankyo, AstraZeneca sign $6bn worth deal for DS-1062

Daiichi Sankyo has signed a global development and commercialisation deal worth up to $6bn with AstraZeneca for its cancer drug candidate DS-1062.